Filtered By:
Drug: Actos

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 156 results found since Jan 2013.

Protective Role of Peroxisome Proliferator-Activated Receptor-{gamma} in the Development of Intracranial Aneurysm Rupture Basic Sciences
Conclusions— Our data showed that the activation of macrophage PPAR protects against the development of aneurysmal rupture. PPAR in inflammatory cells may be a potential therapeutic target for the prevention of aneurysmal rupture.
Source: Stroke - May 22, 2015 Category: Neurology Authors: Shimada, K., Furukawa, H., Wada, K., Korai, M., Wei, Y., Tada, Y., Kuwabara, A., Shikata, F., Kitazato, K. T., Nagahiro, S., Lawton, M. T., Hashimoto, T. Tags: Animal models of human disease, Cerebral Aneurysm, AVM, & Subarachnoid hemorrhage, Aneurysm, AVM, hematoma Basic Sciences Source Type: research

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
Publication date: Available online 23 June 2015 Source:The Lancet Neurology Background A systematic assessment of potential disease-modifying compounds for Parkinson's disease concluded that pioglitazone could hold promise for the treatment of patients with this disease. We assessed the effect of pioglitazone on the progression of Parkinson's disease in a multicentre, double-blind, placebo-controlled, futility clinical trial. Methods Participants with the diagnosis of early Parkinson's disease on a stable regimen of 1 mg/day rasagiline or 10 mg/day selegiline were randomly assigned (1:1:1) to 15 mg/day pioglitazone, 45 mg...
Source: The Lancet Neurology - June 24, 2015 Category: Neurology Source Type: research

Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
Publication date: Available online 11 August 2015 Source:The Lancet Diabetes & Endocrinology Author(s): Miles Fisher, Mark C Petrie, Philip D Ambery, Jill Donaldson, John J V McMurray, June Ye Background Albiglutide is a glucagon-like peptide-1 receptor agonist, a new class of drugs used to treat type 2 diabetes. We did a prospective meta-analysis of the cardiovascular safety of albiglutide as stipulated by the US Food and Drug Administration recommendations for the assessment of new treatments for diabetes. Methods We did a meta-analysis of eight phase 3 trials and one phase 2b trial in which patients wer...
Source: The Lancet Diabetes and Endocrinology - August 12, 2015 Category: Endocrinology Source Type: research

Neuroprotective effects of pioglitazone against transient cerebral ischemic reperfusion injury in diabetic rats: Modulation of antioxidant, anti-inflammatory, and anti-apoptotic biomarkers.
CONCLUSIONS: Pioglitazone is endowed with neuroprotective properties which are probably mediated by its antioxidant, anti-inflammatory, and anti-apoptotic mechanisms hence may provide a successful agent for the management of ischemic stroke. PMID: 26398383 [PubMed - in process]
Source: Pharmacological Reports - September 26, 2015 Category: Drugs & Pharmacology Authors: El-Sahar AE, Safar MM, Zaki HF, Attia AS, Ain-Shoka AA Tags: Pharmacol Rep Source Type: research

Diabetes Drug May Help Prevent Second Stroke
Actos reduced risk by 24 percent in people with insulin resistance, research showed
Source: WebMD Health - February 17, 2016 Category: Consumer Health News Source Type: news

Diabetes Drug May Help Prevent Second Stroke: Study
Actos reduced risk by 24 percent in people with insulin resistance, research showed
Source: U.S. News - Health - February 17, 2016 Category: Consumer Health News Source Type: news

Pioglitazone for Secondary Prevention in Vascular Disease? (FREE)
By Joe Elia Edited by Jaye Elizabeth Hefner, MD Pioglitazone, which lowers insulin resistance, may help in the secondary prevention of vascular events, suggests a study presented at the International Stroke Conference and published in the New England …
Source: Physician's First Watch current issue - February 18, 2016 Category: Primary Care Source Type: news

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
New England Journal of Medicine, Ahead of Print.
Source: New England Journal of Medicine - February 17, 2016 Category: Internal Medicine Tags: article Source Type: research

Diabetes Drug May Help Prevent Second Stroke: Study
Actos reduced risk by 24 percent in people with insulin resistance, research showed
Source: WebMD Health - February 17, 2016 Category: Consumer Health News Source Type: news

PodMed: A Medical News Roundup From Johns Hopkins (with audio)
(MedPage Today) -- This week's topics include testosterone in older men, carotid procedures in those without symptoms, pioglitazone after a stroke, and managing Ebola in the U.S. and Europe
Source: MedPage Today Cardiovascular - February 20, 2016 Category: Cardiology Source Type: news

Feb 19 Cardiology NewsFeb 19 Cardiology News
Carotid stenting vs surgery, leadless pacing, the CMS decision on Watchman, pioglitazone after stroke, and subretinal bleeding with antithrombins are discussed by Dr John Mandrola this week. theheart.org on Medscape
Source: Medscape Cardiology Headlines - February 19, 2016 Category: Cardiology Tags: Cardiology News Source Type: news

Diabetes Drug May Stop Stroke, Help Lipids
Pioglitazone may prevent repeated cardiovascular events in some patients. Combined with omega-3 fatty acids, the drug also can improve lipid metabolism.
Source: ConsultantLive - March 1, 2016 Category: Internal Medicine Authors: Mark L. Fuerst Tags: Cardiovascular Diseases News Diabetes Source Type: news

The IRIS (Insulin Resistance Intervention after Stroke) trial: A new perspective on pioglitazone
Source: Journal of Diabetes - June 7, 2016 Category: Endocrinology Authors: Silvio E. Inzucchi, Karen L. Furie Tags: Commentary Source Type: research

Actos After Stroke May Prevent Diabetes (CME/CE)
(MedPage Today) -- Treatment appears to stop progression from pre-diabetes
Source: MedPage Today Cardiovascular - June 15, 2016 Category: Cardiology Source Type: news

Pioglitazone Slows Progression to Type 2 Diabetes: More IRIS DataPioglitazone Slows Progression to Type 2 Diabetes: More IRIS Data
New and previously reported data from the IRIS trial prompt discussion of reevaluating the role of now-generic pioglitazone in the treatment and prevention of diabetes and stroke. Medscape Medical News
Source: Medscape Diabetes Headlines - June 17, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news